A key stakeholder association is calling for FDA to regulate germline and somatic genetic testing, advocating for creation of best practices to communicate next generation sequencing test results to patients and also suggesting reimbursement policy changes that would encourage appropriate use of genetic testing. The proposals are part of an updated policy statement on next-generation sequencing, specifically for cancer susceptibility testing, clarifying the American Society for Clinical Oncologists' policy on issues pertaining to the technology and addressing two widely debated...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.